MA37866A1 - Dérivés de type aza-indazole ou diaza-indazole pour le traitement de la douleur - Google Patents

Dérivés de type aza-indazole ou diaza-indazole pour le traitement de la douleur

Info

Publication number
MA37866A1
MA37866A1 MA37866A MA37866A MA37866A1 MA 37866 A1 MA37866 A1 MA 37866A1 MA 37866 A MA37866 A MA 37866A MA 37866 A MA37866 A MA 37866A MA 37866 A1 MA37866 A1 MA 37866A1
Authority
MA
Morocco
Prior art keywords
indazole
pain
treatment
diaza
aza
Prior art date
Application number
MA37866A
Other languages
Arabic (ar)
English (en)
Other versions
MA37866B1 (fr
Inventor
Pierre Sokoloff
Frédéric Cachoux
Original Assignee
Pf Medicament
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pf Medicament filed Critical Pf Medicament
Publication of MA37866A1 publication Critical patent/MA37866A1/fr
Publication of MA37866B1 publication Critical patent/MA37866B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La présente invention concerne un composé de formule (i) suivante ou un sel ou solvate pharmaceutiquement acceptable de celui-ci, un tautomère de celui-ci ou un stéréo-isomère ou un mélange de stéréo-isomères de celui-ci dans des proportions quelconques, tel qu'un mélange d'énantiomères, notamment un mélange racémique, destiné à être utilisé dans le traitement de la douleur.
MA37866A 2012-07-27 2015-02-23 Dérivés de type aza-indazole ou diaza-indazole pour le traitement de la douleur MA37866B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP12305922.2A EP2689778A1 (fr) 2012-07-27 2012-07-27 Dérivés de type azaindazole ou diazaindazole pour le traitement de la douleur
PCT/EP2013/065907 WO2014016433A1 (fr) 2012-07-27 2013-07-29 Dérivés de type aza-indazole ou diaza-indazole pour le traitement de la douleur

Publications (2)

Publication Number Publication Date
MA37866A1 true MA37866A1 (fr) 2016-05-31
MA37866B1 MA37866B1 (fr) 2016-12-30

Family

ID=48948392

Family Applications (1)

Application Number Title Priority Date Filing Date
MA37866A MA37866B1 (fr) 2012-07-27 2015-02-23 Dérivés de type aza-indazole ou diaza-indazole pour le traitement de la douleur

Country Status (29)

Country Link
US (1) US9381195B2 (fr)
EP (2) EP2689778A1 (fr)
JP (2) JP6456823B2 (fr)
KR (1) KR102120505B1 (fr)
CN (1) CN104684554B (fr)
AU (1) AU2013294920B2 (fr)
BR (1) BR112015001502B1 (fr)
CA (1) CA2879595C (fr)
CY (1) CY1118478T1 (fr)
DK (1) DK2877177T3 (fr)
ES (1) ES2612349T3 (fr)
HK (1) HK1207302A1 (fr)
HR (1) HRP20170104T1 (fr)
HU (1) HUE032919T2 (fr)
IL (1) IL236917A (fr)
LT (1) LT2877177T (fr)
MA (1) MA37866B1 (fr)
MX (1) MX363605B (fr)
MY (1) MY183398A (fr)
NZ (1) NZ705253A (fr)
PL (1) PL2877177T3 (fr)
PT (1) PT2877177T (fr)
RS (1) RS55646B1 (fr)
RU (1) RU2640046C2 (fr)
SI (1) SI2877177T1 (fr)
TN (1) TN2015000034A1 (fr)
UA (1) UA116107C2 (fr)
WO (1) WO2014016433A1 (fr)
ZA (1) ZA201501209B (fr)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR074052A1 (es) 2008-10-22 2010-12-22 Array Biopharma Inc Compuestos pirazolo{1,5-a}pirimidina sustituida como inhibidores de trk cinasa
AR077468A1 (es) 2009-07-09 2011-08-31 Array Biopharma Inc Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa
CR20170098A (es) 2010-05-20 2017-07-17 Array Biopharma Inc Compuestos macrociclicos como inhibidores de quinasa trk
EP2689778A1 (fr) * 2012-07-27 2014-01-29 Pierre Fabre Medicament Dérivés de type azaindazole ou diazaindazole pour le traitement de la douleur
WO2015143652A1 (fr) * 2014-03-26 2015-10-01 Merck Sharp & Dohme Corp. Inhibiteurs de la kinase trka, compositions et méthodes associées
ES2971157T3 (es) * 2014-10-06 2024-06-03 Apm Therapeutics 1 Inc Compuestos de triazolopiridina y métodos para el tratamiento de la fibrosis quística
JP6914834B2 (ja) 2014-11-16 2021-08-04 アレイ バイオファーマ インコーポレイテッド （Ｓ）−Ｎ−（５−（（Ｒ）−２−（２，５−ジフルオロフェニル）−ピロリジン−１−イル）−ピラゾロ［１，５−ａ］ピリミジン−３−イル）−３−ヒドロキシピロリジン−１−カルボキサミド硫酸水素塩の結晶形
WO2016096709A1 (fr) 2014-12-16 2016-06-23 Eudendron S.R.L. Dérivés hétérocycliques modulant l'activité de certaines protéines kinases
AU2016344058A1 (en) 2015-10-26 2018-05-17 Array Biopharma Inc. Point mutations in Trk inhibitor-resistant cancer and methods relating to the same
US10045991B2 (en) 2016-04-04 2018-08-14 Loxo Oncology, Inc. Methods of treating pediatric cancers
RU2751767C2 (ru) 2016-04-04 2021-07-16 Локсо Онколоджи, Инк. Жидкие составы (s)-n-(5-((r)-2-(2,5-дифторфенил)пирролидин-1-ил)пиразоло[1,5-a]пиримидин-3-ил)-3-гидроксипирролидин-1-карбоксамида
KR102566858B1 (ko) 2016-05-18 2023-08-11 어레이 바이오파마 인크. (s)-n-(5-((r)-2-(2,5-디플루오로페닐)피롤리딘-1-일)-피라졸로[1,5-a]피리미딘-3-일)-3-히드록시피롤리딘-1-카르복사미드의 제조 방법
US10246462B2 (en) 2016-09-09 2019-04-02 Flx Bio, Inc. Chemokine receptor modulators and uses thereof
JOP20190092A1 (ar) 2016-10-26 2019-04-25 Array Biopharma Inc عملية لتحضير مركبات بيرازولو[1، 5-a]بيريميدين وأملاح منها
WO2018079759A1 (fr) * 2016-10-31 2018-05-03 塩野義製薬株式会社 Hétérocycle fusionné ayant une activité inhibitrice de trka et dérivé carbocycle fusionné
JOP20190213A1 (ar) 2017-03-16 2019-09-16 Array Biopharma Inc مركبات حلقية ضخمة كمثبطات لكيناز ros1
JP7322140B6 (ja) * 2018-05-02 2024-02-21 ジェイダブリュ ファーマシューティカル コーポレーション 新規なヘテロサイクル誘導体
KR102129114B1 (ko) * 2018-07-26 2020-07-02 주식회사 온코파마텍 TrkA 저해 활성을 갖는 화합물 및 이를 유효성분으로 함유하는 통증의 예방 또는 치료용 약학적 조성물
EP3725777A1 (fr) * 2019-04-17 2020-10-21 Rottapharm Biotech S.r.l. Benzo- et pyrido-pyrazoles en tant qu`inhibiteurs de protéine kinase
CN110105356B (zh) * 2019-05-31 2022-04-01 四川国康药业有限公司 一种氮杂吲哚类化合物及其制备方法和用途
CN110935250A (zh) 2019-12-10 2020-03-31 科沃斯机器人股份有限公司 空气净化设备

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1134439C (zh) 1997-03-19 2004-01-14 艾博特股份有限两合公司 吡咯并[2,3d]嘧啶类化合物及它们作为酪氨酸激酶抑制剂的用途
EP1215208B1 (fr) 1997-10-27 2006-07-12 Agouron Pharmaceuticals, Inc. Dérivées de 4-aminothiazole, leur préparation et leur utilisation comme inhibiteurs des kinases cycline-depenents
AP2001002194A0 (en) 2000-06-22 2002-12-21 Pfizer Novel process for the preparation of pyrazolopyrimidinones.
SE0301906D0 (sv) * 2003-06-26 2003-06-26 Astrazeneca Ab New compounds
DE102004061288A1 (de) 2004-12-14 2006-06-29 Schering Ag 3-Amino-Pyrazolo[3,4b]pyridine als Inhibitoren von Proteintyrosinkinasen, deren Herstellung und Verwendung als Arzneimittel
BRPI0614884A2 (pt) * 2005-08-25 2011-04-19 Hoffmann La Roche inibidores de p38 map cinase e métodos para uso dos mesmos
US20100056516A1 (en) 2006-07-17 2010-03-04 Williams Peter D 1-hydroxy naphthyridine compounds as anti-hiv agents
JP5302896B2 (ja) * 2006-12-20 2013-10-02 ネルビアーノ・メデイカル・サイエンシーズ・エツセ・エルレ・エルレ 癌治療のためのキナーゼ阻害剤としてのインダゾール誘導体
WO2008089307A2 (fr) * 2007-01-18 2008-07-24 Lexicon Pharmaceuticals, Inc. Méthodes et compositions utilisés dans le traitement de la douleur, de l'inflammation et du cancer
WO2008112695A2 (fr) * 2007-03-12 2008-09-18 Irm Llc Inhibiteurs de protéine kinase et procédés d'utilisation de ceux-ci
BRPI0814628B1 (pt) * 2007-07-20 2022-04-05 Nerviano Medical Sciences S.R.L. Derivados ativos de indazol substituídos como inibidores da quinase
JP5580332B2 (ja) * 2008-12-18 2014-08-27 ネルビアーノ・メデイカル・サイエンシーズ・エツセ・エルレ・エルレ キナーゼ阻害剤として活性な置換インダゾール誘導体
FR2970967B1 (fr) * 2011-01-27 2013-02-15 Pf Medicament Derives de type azaindazole ou diazaindazole comme medicament
EP2689778A1 (fr) * 2012-07-27 2014-01-29 Pierre Fabre Medicament Dérivés de type azaindazole ou diazaindazole pour le traitement de la douleur

Also Published As

Publication number Publication date
HRP20170104T1 (hr) 2017-03-24
MX2015001009A (es) 2015-06-04
KR20150038295A (ko) 2015-04-08
BR112015001502B1 (pt) 2023-03-07
MX363605B (es) 2019-03-26
EP2689778A1 (fr) 2014-01-29
ZA201501209B (en) 2016-03-30
AU2013294920B2 (en) 2017-08-24
US9381195B2 (en) 2016-07-05
WO2014016433A1 (fr) 2014-01-30
JP2015522650A (ja) 2015-08-06
KR102120505B1 (ko) 2020-06-08
US20150190394A1 (en) 2015-07-09
HK1207302A1 (en) 2016-01-29
HUE032919T2 (hu) 2017-11-28
RS55646B1 (sr) 2017-06-30
SI2877177T1 (sl) 2017-02-28
CA2879595C (fr) 2020-07-28
RU2640046C2 (ru) 2017-12-26
BR112015001502A2 (pt) 2017-07-04
EP2877177A1 (fr) 2015-06-03
JP2019031542A (ja) 2019-02-28
RU2015106434A (ru) 2016-09-20
JP6732855B2 (ja) 2020-07-29
LT2877177T (lt) 2017-01-25
TN2015000034A1 (en) 2016-06-29
EP2877177B1 (fr) 2016-10-26
DK2877177T3 (en) 2017-02-06
UA116107C2 (uk) 2018-02-12
CN104684554A (zh) 2015-06-03
NZ705253A (en) 2017-05-26
IL236917A (en) 2016-11-30
AU2013294920A1 (en) 2015-03-12
MY183398A (en) 2021-02-18
CN104684554B (zh) 2017-05-10
ES2612349T3 (es) 2017-05-16
PT2877177T (pt) 2017-02-06
JP6456823B2 (ja) 2019-01-23
MA37866B1 (fr) 2016-12-30
CA2879595A1 (fr) 2014-01-30
CY1118478T1 (el) 2017-07-12
PL2877177T3 (pl) 2017-04-28

Similar Documents

Publication Publication Date Title
MA37866A1 (fr) Dérivés de type aza-indazole ou diaza-indazole pour le traitement de la douleur
GEP20207105B (en) 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2yl carbamate derivatives as magl inhibitors
EA201690247A1 (ru) Аминометилбиарильные производные-ингибиторы фактора d комплемента и их применения
EA201500544A1 (ru) НОВЫЕ БИЦИКЛИЧЕСКИЕ СОЕДИНЕНИЯ И ИХ ПРИМЕНЕНИЕ В КАЧЕСТВЕ АНТИБАКТЕРИАЛЬНЫХ АГЕНТОВ И ИНГИБИТОРОВ β-ЛАКТАМАЗ
MX2015017861A (es) Derivados de benzotiofeno como inhibidores del receptor de estrogeno.
EA201592256A1 (ru) Производные имидазопирролидинона и их применение при лечении заболеваний
BR112016010080A8 (pt) compostos de pirazolopirimidina, composição farmacêutica e seu uso
EA201590371A1 (ru) 1,4-дизамещенные аналоги пиридазина и способы лечения связанных с дефицитом smn состояний
EA201491362A1 (ru) Анестезирующие соединения и способы их применения
TN2014000122A1 (en) 1 - arylcarbonyl - 4 - oxy - piperidine compounds useful for the treatment of neurodegenerative diseases
EA201492023A1 (ru) Регуляторы пути комплемента и их применение
MD4659B1 (ro) Polimorf al inhibitorilor SYK
EA201592255A1 (ru) Производные пиразолопирролидин-4-она в качестве ингибиторов вет и их применение при лечении заболевания
EA201500298A1 (ru) Алкоксипиразолы в качестве активаторов растворимой гуанилатциклазы
MX2015011723A (es) Proceso para la preparacion de una sal de sodio de (2s, 5r) -2-carboxamido-7-oxo-6-sulfooxi-1,6-diaza-biciclo[3.2.1]-octano.
MX2015003594A (es) Agente terapeutico o profilactico para sindrome de lisis tumoral.
TN2014000112A1 (en) Ep1 receptor ligands
EP3412668A3 (fr) Un inhibiteur de la phosphatidylinositol-3-kinase gamma
MX364400B (es) Compuestos de tetraciclina.
EA201600434A1 (ru) Применение производных бензимидазолпролина
EA201400064A1 (ru) Офтальмологическая фармацевтическая композиция для местного применения, которая содержит регорафениб
CA2922375C (fr) Formes de sels d'alpha-tea: compositions et utilisations therapeutiques
EA201490573A1 (ru) Соединение бензотиазолона
SG10201901578UA (en) Processes for the preparation of pyrimidinylcyclopentane compounds
PH12015502703A1 (en) Pharmaceutical compositions